Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity

Hervier, B.; Devilliers, H.; Stanciu, R.; Meyer, Alain; Uzunhan, Y.; Masseau, A.; Dubucquoi, Sylvain; Hatron, Pierre‐Yves; Musset, Lucile; Wallaert, B.; Nunès, Hilario; Maisonobe, Thierry; Olsson, Nils‐Olivier; Adoue, D.; Arlet, P.; Sibilia, Jean; Guiguet, Marguerite; Lauque, D.; Amoura, Zahir; Hachulla, É.; Hamidou, M.; Benveniste, Olivier

doi:10.1016/j.autrev.2012.06.006

Cited by 255 publications

(215 citation statements)

References 26 publications

Supporting

Mentioning

183

Contrasting

Unclassified

Order By: Relevance

“…Antisynthetase syndrome (ASS) is characterized as inflammatory myositis, fever, arthritis, Raynaud's phenomenon, mechanic's hands, and interstitial lung disease (ILD) associated with the expression of anti-tRNA synthetase antibodies (ARS) [1]. Anti-Jo-1 (anti-histidyl) antibody is the most common, but other anti-ARS including anti-PL-12, anti-PL-7, anti-OJ, and anti-EJ tRNA-synthetase antibodies are now routinely diagnosed in Europe using immunoblot assays [2].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Pulmonary Involvement Between Patients Expressing Anti-PL-7 and Anti-Jo-1 Antibodies

Tomonaga

Sakamoto

Ishimatsu

et al. 2014

Lung

View full text Add to dashboard Cite

Anti-PL-7 is an anti-tRNA synthetase antibody (ARS) and interstitial lung disease (ILD) is the most frequent complication of anti-PL-7-associated antisynthetase syndrome (ASS).However, the features of ILD have not been fully elucidated. The present study retrospectively compares seven and 15 patients who were positive for anti-PL-7 and anti-Jo-1 antibodies, respectively. The features of ILD did not significantly differ between the two groups, but the ratio of lymphocytes in bronchoalveolar lavage fluid was higher in the Jo-1, than in the PL-7 group. High-resolution computed tomography revealed nonspecific interstitial pneumonia in all patients in the PL-7 group and organizing pneumonia in four of the 15 patients in the Jo-1 group. These findings suggest that pulmonary complications slightly differ between patients expressing anti-PL-7 and anti-Jo-1 antibodies. Further studies are required to clarify the features of ILD associated with PL-7.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Thus, the features of each ASS have become clearer [3,4]. Interstitial lung disease associated with ARS is the most prevalent ASS manifestation and it is the main cause of morbidity and mortality in ASS [1,3], [5]. Anti-PL-7 antibody is directed against threonyl-tRNA synthetase, and it accounts for 10% -15% of all ARS cases [6].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Pulmonary Involvement Between Patients Expressing Anti-PL-7 and Anti-Jo-1 Antibodies

Tomonaga

Sakamoto

Ishimatsu

et al. 2014

Lung

View full text Add to dashboard Cite

show abstract

“…However, although rarely reported, PH in ASS patients could be related to any of these aetiologies, the most common of which would theoretically be PH due to ILD (PH-ILD) and PAH. Indeed, ILD is the most frequent manifestation of ASS and some patients with ASS may present signs of SSc [1,2,14], which often causes PAH or PH-ILD [7,8,15,16]. Conversely, specific left heart dysfunction seems rare in myositis [17].…”

Section: Introductionmentioning

confidence: 99%

Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival

et al. 2013

Self Cite

View full text Add to dashboard Cite

Antisynthetase syndrome is characterised by the association of interstitial lung disease and myositis with different anti-tRNA-synthetase antibodies. The occurrence, aetiology and prognosis of pulmonary hypertension have not yet been evaluated.Among 203 consecutive patients, transthoracic echocardiogram and right heart catheterisation results were retrospectively analysed in the light of clinico-biological, morphological and functional parameters. Definitions of pulmonary hypertension were based on the European Society of Cardiology/European Respiratory Society 2009 guidelines, with severe pulmonary hypertension being defined by a mean pulmonary arterial pressure .35 mmHg.Pulmonary hypertension was suspected by transthoracic echocardiogram in 47 (23.2%) cases, corresponding to pulmonary hypertension ''possible'' (n527, 13.3%) or ''likely'' (n520, 9.9%). Right heart catheterisation was performed in 21 patients, excluding pulmonary hypertension in five and confirming pre-capillary pulmonary hypertension in 16 (7.9%). Although related to interstitial lung disease in all cases, pre-capillary pulmonary hypertension was severe in 13 (81.3%) patients (mean¡SD pulmonary arterial pressure 46¡9 mmHg), frequently associated with low cardiac index (mean¡SD 2.3¡0.8 L?min -1 ?m -2 ) and high forced vital capacity/diffusing capacity of the lung for carbon monoxide ratio (2.5¡0.6). Pulmonary hypertension was significantly associated with a lower survival rate (p,0.001), with a 3-year survival rate of 58%.The occurrence of pulmonary hypertension in antisynthetase syndrome is significant and dramatically worsens the prognosis. Although systematically associated with interstitial lung disease, pulmonary hypertension was usually severe, suggesting a specific pulmonary vascular involvement. @ERSpublications PH in antisynthetase syndrome significantly worsens the prognosis, suggesting a specific pulmonary vascular involvement

show abstract

“…Warto podkreślić, że przeciwciała anty-Jo-1 zwykle tabela 3. Autoprzeciwciała swoiste dla zapalenia mięśni [16]. Dodatkowo u pacjentów chorujących na zapalenie mięśni związane z opisywaną grupą przeciwciał stwierdza się charakterystyczny obraz histologiczny bioptatu zmienionego mięśnia -limfocytarny naciek zapalny dotyczący omięsnej i lokalizujący się około-pęczkowo.…”

Section: Przeciwciała Antysyntetazoweunclassified

Special papers Diagnostic and therapeutic advances in dermatomyositis

Samotij¹,

Szczęch²,

Reich³

2015

View full text Add to dashboard Cite

StreSzczenieZapalenie skórno-mięśniowe (dermatomyositis -DM) zalicza się do grupy tzw. idiopatycznych miopatii zapalnych (ang. idiopathic inflammatory myopathies -IIM). Schorzenie to ma podłoże autoimmunologiczne, cechuje się obecnością zmian skórnych i/lub objawami zapalenia mięśni. Wyróżnia się tzw. klasyczną postać DM, postać dziecięcą DM oraz paraneoplastyczną DM, DM indukowane lekami i DM bez zaję-cia mięśni. Ostatnio obserwuje się dynamiczny postęp w identyfikacji nowych autoprzeciwciał towarzyszących poszczególnym odmianom DM, w tym anty-TIF1, anty-NXP2, anty-SAE czy anty-MDA5. Prawdopodobnie w niedalekiej przyszłości przyczyni się on do zwiększenia częstości rozpoznawania DM i jego poszczególnych odmian, lepszej stratyfikacji pacjentów pod względem ryzyka zajęcia poszczególnych narządów wewnętrznych oraz wpłynie na całościową poprawę wyników leczenia. Obecnie glikokortykosteroidy są podstawą terapii DM, jednak wprowadzenie do lecznictwa szeregu nowych leków immunomodulujących i immunosupresyjnych, w tym leków biologicznych, wiąże się ze znaczącym zwiększeniem przeżywalności pacjentów z tą chorobą. W niniejszej pracy dokonano przeglądu piśmiennictwa na temat najnowszych trendów w diagnostyce i leczeniu DM. AbStrActDermatomyositis (DM) is one of the so-called idiopathic inflammatory myopathies (IIM). Dermatomyositis is an autoimmune disorder characterized by the presence of cutaneous lesions and/or symptoms of muscle involvement with the following variants: the "classic" variant of DM, juvenile DM, paraneoplastic DM, drug-induced DM and amyopathic DM. Dynamic discoveries of novel autoantibodies, including anti-TIF1, anti-NXP2, anti-SAE or anti-MDA5, related to certain DM variants, have been described in recent years. It seems that these antibodies will contribute to better recognition of DM and its particular variants, a better risk stratification for predicting internal organ involvement, and to a global improvement of treatment outcome. Corticosteroids remain the mainstay of DM therapy, but new immunomodulatory and immunosuppressive agents, including biologicals, resulted in a significant increase of the survival rate of DM patients. Here, we review the current literature data on DM with special emphasis on new trends in its diagnostics and treatment.

show abstract

Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity

Cited by 255 publications

References 26 publications

Comparison of Pulmonary Involvement Between Patients Expressing Anti-PL-7 and Anti-Jo-1 Antibodies

Comparison of Pulmonary Involvement Between Patients Expressing Anti-PL-7 and Anti-Jo-1 Antibodies

Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival

Special papers Diagnostic and therapeutic advances in dermatomyositis

Contact Info

Product

Resources

About